WallStreetZenWallStreetZen

NYSEMKT: SCPX
Scorpius Holdings Inc Stock

$0.11+0.01 (+10%)
Updated May 24, 2024
SCPX Price
$0.11
Fair Value Price
N/A
Market Cap
$3.78M
52 Week Low
$0.07
52 Week High
$0.89
P/E
-0.06x
P/B
0.12x
P/S
1.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.99M
Earnings
-$45.22M
Gross Margin
60.9%
Operating Margin
-643.5%
Profit Margin
-646.4%
Debt to Equity
0.72
Operating Cash Flow
-$32M
Beta
0.7
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

SCPX Overview

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company is headquartered in Durham, North Carolina and currently employs 30 full-time employees. The firm is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. The company is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SCPX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SCPX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SCPX is good value based on its book value relative to its share price (0.12x), compared to the US Biotechnology industry average (6.08x)
P/B vs Industry Valuation
SCPX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SCPX due diligence checks available for Premium users.

Be the first to know about important SCPX news, forecast changes, insider trades & much more!

SCPX News

Valuation

SCPX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.06x
Industry
15.58x
Market
32.03x

SCPX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.12x
Industry
6.08x
SCPX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SCPX's financial health

Profit margin

Revenue
$4.8M
Net Income
-$5.4M
Profit Margin
-111.6%
SCPX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SCPX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$51.0M
Liabilities
$22.7M
Debt to equity
0.72
SCPX's short-term liabilities ($10.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SCPX's long-term liabilities ($12.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SCPX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SCPX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$1.1M
Investing
$2.1M
Financing
-$6.2M
SCPX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SCPX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
SCPX$3.78M+0.96%-0.06x0.12x
SXTP$3.82M+10.14%-0.30x0.53x
CMND$3.65M+2.22%-0.04x0.72x
ZVSA$3.60M+0.47%-0.00x0.32x
THAR$3.60M-6.73%-0.13x0.51x

Scorpius Holdings Stock FAQ

What is Scorpius Holdings's quote symbol?

(NYSEMKT: SCPX) Scorpius Holdings trades on the NYSEMKT under the ticker symbol SCPX. Scorpius Holdings stock quotes can also be displayed as NYSEMKT: SCPX.

If you're new to stock investing, here's how to buy Scorpius Holdings stock.

What is the 52 week high and low for Scorpius Holdings (NYSEMKT: SCPX)?

(NYSEMKT: SCPX) Scorpius Holdings's 52-week high was $0.89, and its 52-week low was $0.07. It is currently -88.14% from its 52-week high and 50% from its 52-week low.

How much is Scorpius Holdings stock worth today?

(NYSEMKT: SCPX) Scorpius Holdings currently has 36,031,964 outstanding shares. With Scorpius Holdings stock trading at $0.11 per share, the total value of Scorpius Holdings stock (market capitalization) is $3.78M.

Scorpius Holdings stock was originally listed at a price of $669.90 in Jul 24, 2013. If you had invested in Scorpius Holdings stock at $669.90, your return over the last 10 years would have been -99.98%, for an annualized return of -58.36% (not including any dividends or dividend reinvestments).

How much is Scorpius Holdings's stock price per share?

(NYSEMKT: SCPX) Scorpius Holdings stock price per share is $0.11 today (as of May 24, 2024).

What is Scorpius Holdings's Market Cap?

(NYSEMKT: SCPX) Scorpius Holdings's market cap is $3.78M, as of May 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Scorpius Holdings's market cap is calculated by multiplying SCPX's current stock price of $0.11 by SCPX's total outstanding shares of 36,031,964.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.